Cytokinetics (CYTK) Common Equity (2016 - 2025)
Cytokinetics (CYTK) has disclosed Common Equity for 16 consecutive years, with -$659.6 million as the latest value for Q4 2025.
- Quarterly Common Equity changed N/A to -$659.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$659.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$659.6 million for FY2025, N/A changed from the prior year.
- Common Equity for Q4 2025 was -$659.6 million at Cytokinetics, down from -$521.1 million in the prior quarter.
- The five-year high for Common Equity was $249.0 million in Q3 2021, with the low at -$659.6 million in Q4 2025.
- Average Common Equity over 5 years is -$148.6 million, with a median of -$107.9 million recorded in 2022.
- The sharpest move saw Common Equity skyrocketed 575.69% in 2022, then plummeted 3646.12% in 2025.
- Over 5 years, Common Equity stood at $243.9 million in 2021, then plummeted by 144.25% to -$107.9 million in 2022, then crashed by 258.04% to -$386.3 million in 2023, then soared by 96.4% to -$13.9 million in 2024, then plummeted by 4641.75% to -$659.6 million in 2025.
- According to Business Quant data, Common Equity over the past three periods came in at -$659.6 million, -$521.1 million, and -$368.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.